урактон инструкция по применению цена отзывы аналоги
Главное меню:
Интересное
урактон инструкция по применению цена отзывы аналоги, English - Gemeinsamer Bundesausschuss - G-BA, Federal Joint Committee (Germany) - Wikipedia, German HTA assessments: overview of procedures and - AMNOG-Monitor, Benefit assessment in Germany: implications for price discounts, G-BA Early Advice: How do we prepare for the requirements that the , Who are the members of the G-BA? - German Market Access, ISPOR - Determinants of Added Benefit Ratings in Germany: An .
About the Federal Joint CommitteeThe Federal Joint Committee (G-BA) is the highest decision-making body of the joint self-government of physicians, dentists, hospitals and health insurance funds in Germany.It issues directives for the benefit catalogue of the statutory health insurance funds (GKV) for more than 74 million insured persons and thus specifies which services in medical care are reimbursed by the GKV.read moreBenefit Assessment of Medicinal ProductsThe G-BA must put every new active pharmaceutical ingredient through an early benefit assessment within six months after it is launched on the German market. During the early benefit assessment, the G-BA examines whether the drug is really something new: if it offers patients greater benefit than comparable treatments that are already available.read moreIntroductory videoThe G-BA – explained in four minutesWho is the G-BA and what does it do? The introductory video provides a first overview of the G-BA., Der Gemeinsame Bundesausschuss (G-BA) ist das oberste Beschlussgremium der gemeinsamen Selbstverwaltung der Ärzte, Zahnärzte, Psychotherapeuten, Krankenhäuser und Krankenkassen in Deutschland., The Federal Joint Committee (German: Gemeinsamer Bundesausschuss (G-BA)) refers to a group of German public health agencies that were merged in 2004, under an independent chairman. [1] It is authorized to make binding regulations growing out of health reform bills passed by lawmakers, along with routine decisions regarding healthcare in Germany .
Since the AMNOG (Act on the Reform of the Market for Medicinal Products) entered into force on 1 January 2011, a total of 1215 procedures concerning 531 different medicinal products have been initiated by the G-BA. 1099 of these procedures have been finalised with a resolution (see figure)., Upon market registration, pharmaceutical companies are obliged by law to submit a dossier to the Federal Joint Committee (Gemeinsamer Bundesausschuss, GBA) in order to prove a patient-relevant medical benefit in mortality, morbidity, and health-related quality of life (HRQoL)., There are two Health Technology Assessment (HTA) bodies in Germany: the G-BA (Federal Joint Committee), which is the decision-maker, and the IQWIG (Institute for Quality and Efficiency in Healthcare), which is usually ordered to perform the benefit assessment., 1 representative each from the German Medical Association, the Federation of Private Health Insurance Providers, the German Nurses’ Council, the German Psychotherapy Association, and the German Dental Association in the discussion., CONCLUSIONS: G-BA added benefit ratings are most commonly associated with recognised improvements in morbidity and mortality endpoints, while improvements in safety and quality of life feature less prominently as predictors., Our analysis suggests that in Germany there may be a demonstrated and predictable bias for drugs for fatal diseases. Since January 2011, the German G-BA has evaluated new drugs on their degree of added benefit versus a comparator therapy..